Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone

Launched by IVI BARCELONA · Oct 2, 2015

Keywords

ClinConnect Summary

The aim of this study is to compare predecidualization and endometrial receptivity as gene expression by using subcutaneous progesterone 25 mg/day versus intramuscular progesterone 50 mg/day in healthy women of childbearing age. Both, the two drugs and the doses administered in this clinical trial, are routine clinical practice.

A controlled ovarian stimulation will be previously performed and following routine clinical practice for 10-12 days at standard doses of subcutaneous FSH 150-225 IU/day, according to BMI and number of antral follicles. A GnRH antagonist shall be administered, bein...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female aged between 18 and 34 years
• • BMI between 18 and 28 kg/m2
• • Endometrial thickness \> 7 mm the day of progesterone treatment initiation (day of follicular puncture)
• • Follicular maturation with a single bolus of GnRH agonist
• • Egg donors who undergo a cycle of ovarian stimulation in the IVI Barcelona Centre
• • Egg donors selected in accordance with the requirements of Law 14/2006 of 26 May 2006 on Assisted Human Reproduction Techniques
• • Informed consent has been signed and dated
• Exclusion Criteria:
• • Known allergy to progesterone formulations or their excipients
• • Known allergy to estrogens
• • Known thrombophilias
• • Alcohol, drug or psychotropic medication dependence
• • Concurrent participation in another study
• • Concomitant medication that may interfere with the study medication and ovarian stimulation
• • Failure to comply with the requirements for egg donors in accordance with Law 14/2006 of 26 May 2006 on Assisted Human Reproduction Techniques